Clinical, Neurophysiological and Immunological Peculiarities of Myasthenia Gravis in Patients with Different Histologic Types of Thymoma by Tovazhnyanska, Olena et al.
Galician medical journal 2016
Vol. 23, Issue 4, E201648
DOI: 10.21802/gmj.2016.4.8
Research Article
Clinical, Neurophysiological and Immunological
Peculiarities of Myasthenia Gravis in Patients with
Different Histologic Types of Thymoma
Olena Tovazhnyanska1, Hanna Samoilova1*, Olena Protsenko2, Natalia Remnyova2, Yuri
Kostya3
Abstract
Thymoma is characterized by various clinical manifestations. About half of them are manifested as an asymptomatic course,
others occur in a combination with different syndromes. 25% of patients develop compression of tumor blood vessels,
nerves and organs of the mediastinum or clinical signs of germination of thymic tumor in other organs. 40% of patients
are diagnosed with autoimmune diseases due to dysfunction of the thymus. Generalized myasthenia gravis (75%) is most
frequently observed.
The objective of the research was to study clinical and immunological peculiarities of myasthenia gravis depending on the
size and histological type of thymoma.
Materials and methods. The results of clinical and immunological, instrumental and histological examination of 30 patients
with myasthenia on the background of thymoma were analyzed. The severity of the disease was assessed using clinical
classification of the Myasthenia Gravis Foundation of America (MGFA, 2001).To determine the barrier function of phagocytic
cells, phagocytosis activity of neutrophils was evaluated using the light microscope. The phagocytic index, the phagocytic
number and the index of phagocytosis completion were determined. The suspension culture of Saccharomyces cerevisiae
was used as a microbial agent. Preparations were stained using the Romanovsky-Himze methods. Neutrophilic leukocytes
were separated from leukocyte suspension of peripheral blood. The expression of differentiation clusters CD3+, CD4+
and CD8+ on subpopulation of T- and B-cells were evaluated by indirect ELISA using monoclonal antibodies labeled with
FITC-dye. To diagnose thymoma, we used spiral CT “Marconi” SeleCT/SP. For histologic study thymoma samples were fixed
in 10% neutral formalin for 24 hours. The material was embedded in paraffin after posting through the chloroform in the usual
way; then, sections with the thickness of 5-7 µm were prepared. Preparations were stained with hematoxylin and eosin.
Results and conclusions. The severity of the clinical course of myasthenic syndrome on the background of thymoma
does not depend on tumor size; it depends on the histologic type and immunological imbalance. The severest clinical
picture was observed in patients with type AB thymoma and the least severe course of myasthenic symptoms was found
in patients with lymphoid thymoma (type B1). Lymphoepithelial and epithelial thymomas were accompanied by similar
immunological disorders. The reduction in the levels of CD3+ and CD4+ lymphocyte subpopulations can be used as a reliable
diagnostic criterion. Lymphoid thymomas are characterized by a significant reduction in the indicators of the phagocytic
index, the phagocytic number, and the level of CD8+ lymphocyte subpopulations as well as an increase in the level of CD4+
subpopulations. Surgical treatment as a method of choice in case of radical immunosuppression is indicated for all patients
with confirmed thymoma regardless of its size and histological characteristics.
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Problem statement and analysis of the
recent research
Thymic neoplasms are the most common tumors of the ante-
rior mediastinum including thymoma and carcinoma of the
thymus [1, 2].
Thymomas constitute approximately 20% of mediastinal
tumors; their average incidence is 0.18 cases per 100,000 men
and 0.10 cases per 100,000 women. Thymic carcinomas are
rare tumors and represent less than 15% of all tumors of the
mediastinum. They are more invasive than thymomas having
worse prognosis [1].
The first case of the tumor of the thymus gland was de-
scribed by Lantensau and Kay in 1867. Some publications
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appeared later; however, they were mainly sectional findings.
The term “thymoma”, being offered by Grandhomme and
Schminke in 1900, is used to this day. However, some authors
believe that the term “thymoma” is insufficient, since it refers
only to the organ itself and does not reflect their histogenetic
diversity [1-3].
Thymoma is usually a pale pink or grayish-white node,
often with evident capsules of varying thickness and density.
Multiple primary tumors are less common.
In 90% of cases, the tumor is located in the upper part of
the anterior mediastinum. Thymomas of other localization (in
the middle and posterior mediastinum, etc.) are associated
with aberrant thymic tissue. Tumor size ranges from a few
millimeters to a few tens of centimeters (averaging 6-8 cm)
[2, 3].
Its heterogeneity is associated not only with different con-
tent of T-cells and their precursors in the tumor but with pro-
nounced variability of epithelial cell morphology. Therefore,
modern histogenetic classification includes the existence of
two major subpopulations of thymic epithelial cells, namely
the cortical and medullar thymic epithelial cells, which have
different origins in embryogenesis [2, 3].
According to the latest histological classification of thy-
moma modified in 2004 by the WHO, thymic neoplasms are
distinguished on the basis of histological and immunophe-
notypic affinity to the cortical or medullary layers of thymic
cells. The WHO classification system defines the following
histologic types [1]:
• Type A thymoma is defined as a tumor is composed
of neoplastic thymic epithelial cells that have a spin-
dle/oval shape, lack nuclear atypia, and are accompa-
nied by few, if any, nonneoplastic lymphocytes;
• Type B1 is described as a tumor that resembles the
normal functional thymus and combines large expanses
having an appearance practically indistinguishable from
the normal thymic cortex with areas resembling thymic
medulla;
• Type B2 is a tumor in which the neoplastic epithelial
component appears as scattered large epithelial cells
with vesicular nuclei and distinct nucleoli against a
heavy population of lymphocytes;
• Type B3 corresponds to tumors composed predomi-
nantly of epithelial cells having a round or polygonal
shape and exhibiting no or mild atypia;
• Type AB thymoma is defined as a tumor in which foci
having features of type A thymoma are admixed with
foci showing features of type B thymoma;
• Type C thymoma is defined as a tumor exhibiting clear-
cut cytologic atypia and a set of cytoarchitectural fea-
tures no longer specific to the thymus, but rather analo-
gous to those seen in carcinomas of other organs.
Thymoma is characterized by various clinical manifes-
tations as well. About half of them are manifested as an
asymptomatic course, others occur in a combination with dif-
ferent syndromes. 25% of patients develop compression of
tumor blood vessels, nerves and organs of the mediastinum or
clinical signs of germination of thymic tumor in other organs.
40% of patients are diagnosed with autoimmune diseases due
to dysfunction of the thymus. Generalized myasthenia gravis
(75%) is most frequently observed [2, 3].
The objective of the research was to study clinical and
immunological peculiarities of myasthenia gravis depending
on the size and histological type of thymoma.
1. Materials and methods
The results of clinical and immunological, instrumental and
histological examination of 30 patients (17 women and 13
men) with myasthenia against the background of thymoma
treated at the thoracic department of V.T. Zaitsev Institute of
General and Emergency Surgery of the Ministry of Health
of Ukraine were summarized and analyzed. The severity of
the disease was assessed using clinical classification of the
Myasthenia Gravis Foundation of America (MGFA, 2001) [4,
5].
To determine the barrier function of phagocytic cells,
phagocytosis activity of neutrophils was evaluated using the
light microscope. The phagocytic index (PI), the phagocytic
number (PN) and the phagocytosis completion index (PCI)
were determined. The suspension culture of Saccharomyces
cerevisiae was used as a microbial agent. Preparations were
stained using the Romanovsky-Himze methods. Neutrophilic
leukocytes were separated from leukocyte suspension of pe-
ripheral blood [6, 7].
The expression of differentiation clusters CD3+, CD4+
and CD8+ on subpopulation of T- and B-cells were evaluated
by indirect ELISA using monoclonal antibodies labeled with
FITC-dye [7].
To diagnose thymoma, we used spiral CT “Marconi” Se-
leCT/SP. For histologic study thymoma samples were fixed
in 10% neutral formalin for 24 hours. The material was em-
bedded in paraffin after posting through the chloroform in the
usual way; then, sections with the thickness of 5-7 µm were
prepared. Preparations were stained with hematoxylin and
eosin.
Statistical analysis of the results was performed using
the software package Statistica 6. The average values and
standard errors were calculated. Types of sign distribution
among patients were determined using the Shapiro-Wilk test;
the equality of variances for a variable was calculated using
the Levene’s test.
The comparison of two groups with normal distribution
was performed using classical Student’s t-test for independent
samples and Student’s t-test with separate estimation of vari-
ances. The Mann-Whitney U test was used as a nonparametric
test. Differences were considered significant at p<0.05.
The control group consisted of 30 practically healthy indi-
viduals.
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2. Results and Discussion
Myasthenia gravis was diagnosed in all patients (manifesta-
tion of the disease at the age of 48.3±9.7 years). According
to clinical classification of the MGFA, at the time of hospi-
talization 7 (23.3%) patients had MGF Class 3A, 13 (43.6%)
patients had MGFA Class 3B, 6 (20%) patients had MGF
Class 4A, and 4 (13.1%) patients had MGF Class 5.
During neurological examination, severe weakness of the
skeletal (average muscle strength of the upper and lower ex-
tremities accounted for 2.5 points) and respiratory muscles,
oropharyngeal weakness (reduced excursion of the soft palate,
difficulty in swallowing, dysphonia) were observed in all pa-
tients. 4 patients required mechanical ventilation (MV).
During electromyography (EMG), a significant decrease
in the amplitude of negative phase M- response in musculus or-
bicularis oculi (0.44±0.2 mV; in the control group – 0.9±0.2
mV; p<0.05), musculus abductor digiti minimi (3.96±1.1
mV; in the control group – 5.1±0.2 mV; p<0.05) and increase
in the response decrement rate (49.02±5.8%, in the control
group – 11.3±0.2%; p<0.05) were observed compared to
those in the control group.
According to the data of spiral CT of the thymus gland,
the size of the thymus increased. In 10 patients, thymoma
was in average 2.1±0.6 in diameter. Clinical myasthenic
syndrome in this group of patients was characterized by a
decrease in muscle strength in the limbs to 2.5-3.0 points as
well as the presence of dysarthria and dysphagia. 2 patients
were diagnosed with the myasthenic crisis thereby requiring
MV.
According to clinical classification of the MGFA, at the
time of hospitalization 2 patients had MGF Class 3A, 4 pa-
tients had MGFA Class 3B, 2 patients had MGF Class 4A,
and 2 patients had MGF Class 5.
11 patients were diagnosed with thymoma being 4.4±0.8
cm in diameter. Dysphagia and dystonia on the background of
muscle weakness being 2.0-3.0 points were detected as well.
Severe course of the disease which required MV was observed
in 1 patient. According to clinical classification of the MGFA,
at the time of hospitalization 3 patients had MGF Class 3A, 5
patients had MGFA Class 3B, 2 patients had MGF Class 4A,
and 1 patient had MGF Class 5.
The largest size of thymoma being 8.3±1.3 cm in diameter
was found in 9 patients; however, the clinical picture of myas-
thenia gravis did not significantly differ from the previous two
groups. According to clinical classification of the MGFA, at
the time of hospitalization 2 patients had MGF Class 3A, 4
patients had MGFA Class 3B, 2 patients had MGF Class 4A,
and 1 patient had MGF Class 5.
The study of the phagocytic function in all patients with
myasthenia and co-existent thymoma revealed significant
(p<0.05) reduction in the PI to 32.4±2.6% (in the control
group – 73.1±9.0%) and the PN to 2.1±0.5 (in the control
group – 3.6±0.1) with the preservation of the PCI within the
control values [6].
The same dynamics of the phagocytic function was ob-
served in all groups of patients regardless of tumor size.
When studying the parameters of T-cell immunity, we found
a significant (p<0.05) reduction in CD4+ to 21.0±9.4% and
CD8+ to 13.0±3.7% (in the control group – 29.0±8.6% and
18.0±4.5%, respectively), the severity of which did not de-
pend on the size of thymoma.
Considering the variability of histological thymoma all the
examined patients were divided into three groups according to
the WHO classification and histological type of thymus gland
tumor.
Group I included 12 patients with histologically confirmed
lymphoepithelial thymoma (type AB according to the WHO
classification) (Fig. 1). The clinical picture of myasthenia
gravis was characterized by considerable generalized muscle
weakness (muscular strength in the legs was 2.5-3.0 points)
and severe bulbar disorders; 8 patients had MGF Class 3B
and 2 patients had MGF Class 4A. 2 patients with MGF Class
5 required MV.
Group II consisted of 8 patients with histologically con-
firmed epithelial thymoma (type B3 according to the WHO
classification). Myasthenia gravis manifested itself as severe
muscle weakness (muscular strength in the extremities of 3.0-
3.5 points) and bulbar disorders. According to clinical classi-
fication of the MGFA, all patients were divided as follows: 2
patients with MGF Class 3A, 3 patients with MGF Class 3B,
2 patients with MGF Class 4A, 1 patient with MGF Class 5.
Group III included 10 patients with lymphoid thymoma (type
B1 according to the WHO classification). The clinical picture
of myasthenia gravis was characterized by severe lesions of
skeletal muscles (muscle strength in the limbs was 3.0-3.5
points) and moderate bulbar disorders; 5 patients had MGF
Class 3A, 2 patients had MGF Class 3B and 2 patients had
MGF Class 4A. 1 patient with MGF Class 5 required MV.
The results of immunological study in patients with myas-
thenia and co-existent thymoma based on histological types
of tumors are presented in Tables 1 and 2. The maximum
reduction in the PI (by 1.5 times) was observed in patients
with type B1 thymoma. In patients with type AB and type
B3 thymoma, the reduction in this indicator was significant as
well; however, it was less pronounced (by 1.1 and 1.2 times
compared to the control group) (Table 1).
The reduction in the PN was observed in groups with
type AB and type B1 thymoma (by 1.3 and 1.2 times, respec-
tively), and in patients with epithelial thymoma, this indicator
increased by 1.2 times. The PCI in patients with epithelial
thymoma increased twofold; in patients of other groups this
indicator did not significantly differ from the control group
(Table 2).
Patients with type AB and type B3 thymoma noticed a sig-
nificant reduction in CD3+ by 1.5 and 1.8 times, respectively,
which was not observed in the group of patients with type B1
thymoma (Table 2).
The level of CD4+ cluster was significantly depressed in
the group of patients with type AB and type B3 thymoma; the
level of CD8+ in these groups was not significantly different
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Figure 1. Thymus. Lymphoepithelial thymoma with lymphoid follicles and germinal centers.
Staining with hematoxylin and eosin.
Magnification: x100.
Table 1. Changes in primary indicators of immunity in patients depending on histological characteristics of thymoma.
Morphological structure of the thymus PI, % PN PCI
Control group, n=30 73.1±9.0 3.6±0.1 1.1±0.2
Patients with lymphoepithelial thymoma (type AB), n=12 65.3±8.7* 2.7±0.5* 1.1±0.3
Patients with epithelial thymoma (type B3), n=8 61.4±10.9* 4.3±1.5* 2.3±0.7*
Patients with lymphoid thymoma (type B1), n=10 47.8±16.9* 2.8±0.4* 1.7±0.8
Note.
* - size differed significantly from that in the control group (p<0.05).
Table 2. Changes in indicators of T-cell immunity in patients with thymoma depending on histological characteristics.
Morphological structure of the thymus CD3+, % CD4+, % CD8+, %
Control group, n=30 52.0±11.4 29.0±8.6 18.0±4.5
Patients with lymphoepithelial thymoma (type AB), n=12 35.6±10.1* 13.8±12.1* 14.3±12.7
Patients with epithelial thymoma (type B3), n=8 28.6±12.9* 15.9±5.1* 13.5±11.5
Patients with lymphoid thymoma (type B1), n=10 49.2±14.7 37.9±7.4* 7.9±3.4*
Note.
* - size differed significantly from that in the control group (p<0.05).
from that in the control group. In patients with lymphoid
thymoma (type B1), CD4+ exceeded the reference value by
1.3 times, and cytotoxic T- lymphocytes (CD8+) were signifi-
cantly depressed (Table 2).
Summarizing the findings it should be noted that myas-
thenic symptoms in patients with thymoma are of general-
ized character and are accompanied by severe weakness of
the skeletal (average muscle strength of the upper and lower
extremities accounted for 2.5 – 3.0 points) and respiratory
muscles, oropharyngeal weakness. According to clinical clas-
sification of the MGFA, 13 (43.6%) patients had MFFA Class
3B and 6 (20%) patients had MFFA Class 4A.
The development of myasthenia gravis in patients with
thymoma is accompanied by immunological disorders in the
form of the reduction in the PI and the PN as well as the levels
of CD4+ and CD8+ clusters. Clinical and immunological
comparison depending on the size of thymoma and its histo-
logic type showed that the severity of myasthenic symptoms
and immunological disorders do not depend on the size of
thymoma. At the same time, various histologic types of thy-
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moma are characterized by various clinical manifestations of
myasthenia gravis and immunological disorders.
For example, lymphoepithelial and epithelial thymomas
were accompanied by considerable weakness of the limbs as
well as bulbar muscles, which was combined with equally
directed impaired T-cell immunity - a significant reduction in
the levels of CD3+ and CD4+ subpopulations and the tendency
to the reduction in the levels of CD8+ clusters.
The differences in immunological disorders were associ-
ated with the primary immune response: myasthenia gravis
secondary to lymphoepithelial thymoma was accompanied
by a significant reduction in the PI and the PN; myasthenia
gravis with co-existent epithelial thymoma was accompanied
by a significant reduction in the PI and increase in the PN and
the PCI.
In case of lymphoid thymoma, myasthenic symptoms are
characterized by a predominance of limb lesions; they are
accompanied by significant (compared to that in the control
group and other groups) reduction in the PI, the PN, subpopu-
lations of CD8+ and increase in CD4+ levels.
Surgical treatment was used in all cases as a radical method
of immunosuppression. It should be noted that 80% of pa-
tients in the postoperative period had a tendency to myasthenic
syndrome regression and reduction in neostigmine methyl-
sulfate dosage. 3% of patients (type AB thymoma) had a
complicated postoperative period (myasthenic crisis), which
required replaceable plasma exchange with the subsequent
administration of glucocorticoids (prednisolone).
3. Conclusions
The severity of the clinical course of myasthenic syndrome
secondary to thymoma does not depend on tumor size; it
depends on the histologic type and immunological imbalance.
The severest clinical picture was observed in patients with
type AB thymoma and the least severe course of myasthenic
symptoms was found in patients with lymphoid thymoma
(type B1).
Lymphoepithelial and epithelial thymomas are accompa-
nied by similar immunological disorders. The reduction in the
levels of CD3+ and CD4+ lymphocyte subpopulations can be
used as a reliable diagnostic criterion.
Lymphoid thymomas are characterized by a significant
reduction in the indicators of the PI, the PN, and the level of
CD8+ lymphocyte subpopulations as well as an increase in
the level of CD4+ subpopulations.
Surgical treatment as a method of choice in case of radical
immunosuppression is indicated for all patients with con-
firmed thymoma regardless of its size and histological charac-
teristics.
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